Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
Anna Grenda, Ewelina Iwan, Izabela Chmielewska, et al.
AMB Express (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Mengwei Zhang, Jinkai Liu, Qiang Xia
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 50
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Xing Kang, Harry Cheuk-Hay Lau, Jun Yu
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101478-101478
Open Access | Times Cited: 41
Critical role of the gut microbiota in immune responses and cancer immunotherapy
Ze-Hua Li, Weixi Xiong, Liang Zhu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 34
Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
Lone Gamrath, Tina H. Pedersen, Mecker G. Möller, et al.
Current Oncology Reports (2025)
Open Access | Times Cited: 4
Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer
Yu Xin, Chenguang Liu, Dan Zang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Despoina Eugenia Kiousi, Antonia Z. Kouroutzidou, Konstantinos Neanidis, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2101-2101
Open Access | Times Cited: 21
Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
Haihong Jiang, Qinlu Zhang
Oncology Letters (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 8
Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review
Rajan Thapa, A Magar, Jesus Shrestha, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access | Times Cited: 7
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
Sreya Duttagupta, Taiki Hakozaki, Bertrand Routy, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9406-9427
Open Access | Times Cited: 13
Analysis of the fecal metagenome in long‐term survivors of pancreas cancer
Jordan Kharofa, David Haslam, Rachael Wilkinson, et al.
Cancer (2023) Vol. 129, Iss. 13, pp. 1986-1994
Open Access | Times Cited: 11
The traditional Chinese medicine and non-small cell lung cancer: from a gut microbiome perspective
Xuelin Wang, Liming Hou, Meng Cui, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 11
A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases
Cong Xu, Mengqi Hao, Xiaohu Zai, et al.
Archives of Microbiology (2024) Vol. 206, Iss. 3
Closed Access | Times Cited: 4
Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy
Jianzhen Shan, Zhen Liu, Songan Chen, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Limosilactobacillus reuteri ZY15 Alleviates Intestinal Inflammation and Barrier Dysfunction via AKT/mTOR/HIF-1α/RORγt/IL-17 Signaling and the Gut Microbiota in ETEC K88-Challenged Mice
Xin Xu, Hongwei Zhang, Kun Meng, et al.
Antioxidants (2025) Vol. 14, Iss. 1, pp. 58-58
Open Access
Sea cucumber polysaccharides overcome immunotherapy resistance in tumor-bearing mice via modulation of gut microbiome
Jiahui Li, Jinhui Jia, Yue Teng, et al.
Food & Function (2025)
Closed Access
Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8+T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice
Zhijun Fan, Yi Zheng, Sheng Li, et al.
BMC Biotechnology (2025) Vol. 25, Iss. 1
Open Access
Enhanced anti-inflammatory activity of chlorogenic acid via folic acid-TPGS-modified liposomes encapsulation: characterization and In vivo evaluation on colitis mice
Qing-qing Li, Jiahui Yan, Zhou Zhi-e, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
Anna Grenda, Ewelina Iwan, Paweł Krawczyk, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6250-6250
Open Access | Times Cited: 16
Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
Małgorzata Frąk, Anna Grenda, Paweł Krawczyk, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5577-5577
Open Access | Times Cited: 13
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
Elio Gregory Pizzutilo, Rebecca Romanò, Laura Roazzi, et al.
Cancer Research (2023) Vol. 83, Iss. 14, pp. 2283-2296
Open Access | Times Cited: 7
Exploring the human microbiome – A step forward for precision medicine in breast cancer
Asmita Jotshi, Krishna Kishore Sukla, Mohammed Monzoorul Haque, et al.
Cancer Reports (2023) Vol. 6, Iss. 11
Open Access | Times Cited: 7
From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy
David Dora, Emőke Szőcs, Ádám Soós, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
Joy Sarkar, Eduardo Cortes Gomez, Takaaki Oba, et al.
World Journal of Oncology (2023) Vol. 14, Iss. 3, pp. 178-187
Open Access | Times Cited: 4
Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non‐small cell lung cancer
Adane Adugna, Yalew Muche, Mohammed Jemal, et al.
Aging Medicine (2024) Vol. 7, Iss. 1, pp. 121-130
Open Access | Times Cited: 1
Maternal obesity increases the risk of hepatocellular carcinoma through the transmission of an altered gut microbiome
Beat Moeckli, Vaihere Delaune, Benoît Gilbert, et al.
JHEP Reports (2024) Vol. 6, Iss. 5, pp. 101056-101056
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top